Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Selexipag Lowers Risk of Morbidity, Mortality Events by 40% in PIII Study
March 17, 2015
- AnGes MG Initiates PIII Study of Nucleotide NF-κB Decoy Oligo for Atopic Dermatitis
March 17, 2015
- ViiV Receives Approval for HIV Infection Treatment Triumeq
March 17, 2015
- Takecab Surged to Top Spot in January Anterio Ranking
March 16, 2015
- Meiji Seika Halts Development of Antiallergic Treatment, Terminating Pact with Amalyte
March 16, 2015
- Eisai Revises Deal with Epizyme on Cancer Therapies
March 13, 2015
- Santen Earns Approval for Preservative-Free Glaucoma Eye Drops
March 13, 2015
- Sanwa Kagaku Names Hata as Successor to Late President Yamamoto
March 13, 2015
- AZ Appoints BMKK’s Taniguchi as Head of R&D
March 13, 2015
- AZ Receives Approval for Bydureon Pen Formulation
March 13, 2015
- Takecab vs PPIs (3): Which Will Come Out on Top? Everything Now in the Hands of Frontline Prescribers
March 13, 2015
- Takeda Transfers HPV Vaccine License to Kaketsuken
March 12, 2015
- Takecab vs PPIs (2): Takecab to Initially Gain Share for H. pylori Eradication?
March 12, 2015
- AZ to Tap Rich Pipelines to Grow as Oncology Powerhouse
March 11, 2015
- Over Half of RA Patients Remained in Remission 1 Year After Stopping Enbrel: Prof. Yamanaka
March 11, 2015
- Alogliptin Demonstrates No Increased Risk of Heart Failure: Takeda
March 11, 2015
- University of Tokyo, Sanofi Collaborate for Joint Drug Discovery Research in Fields of Inflammatory Disease, Oncology
March 11, 2015
- Takecab vs PPIs (1): “Rapid, Sustained Efficacy” Pitted against “Patient Satisfaction”, Will Paradigm Shift Occur?
March 11, 2015
- Announcement: 8th Annual Marketing Excellence Japan 2015 - Westin Tokyo, May 12-13
March 10, 2015
- Astellas Wins US Approval for Antifungal Agent Cresemba
March 10, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…